Core Viewpoint - China Tongru (01763) experienced a significant stock increase of over 10% following the launch of its carbon isotope product and the second phase of its stable isotope base project in Tongcheng, Anhui, which is expected to enhance domestic production capabilities in the medical isotope sector [1] Group 1: Company Developments - The launch event on October 31 marked the initiation of a project that will produce 2,000 kilograms of high-abundance 13CO gas and 4,000 kilograms of 13C urea raw materials annually [1] - The high-abundance 13CO gas is a critical raw material used in urea breath tests for detecting Helicobacter pylori infections [1] - The project signifies a shift from reliance on imported 13CO gas for urea breath diagnostic materials, establishing a fully autonomous supply chain in the medical stable isotope carbon field in China [1] Group 2: Industry Impact - The establishment of this production line is expected to provide a solid foundation for creating a safe and reliable high-end medical isotope supply chain in China [1] - The project represents a comprehensive control over the entire industry chain from key raw materials to end products in the medical stable isotope sector [1]
港股异动 | 中国同辐(01763)午后涨超10% 公司发布碳同位素产品 实现全产业链自主可控